Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1020-1026

  Kavanaugh, Arthur ^a   Mease, Philip J ^b   Gomez Reino, Juan J ^c   Adebajo, Adewale O ^d   Wollenhaupt, Jürgen ^e   Gladman, Dafna D ^f   Lespessailles, Eric ^g   Hall, Stephen ^h   Hochfeld, Marla ⁱ   Hu, Chiachi ⁱ   Hough, Douglas ⁱ   Stevens, Randall M ⁱ   Schett, Georg ^j  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Hosp Clin Univ   (Spain)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e Klinik für Rheumatologie Handchirurgie Rheumazentrum Oberammergau   (Germany)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITÉ D'ORLÉANS   (France)

^h MONASH UNIVERSITY   (Australia)

ⁱ CELGENE CORPORATION   (United States)

^j UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APREMILAST; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CELLULITIS; CLOSTRIDIUM INFECTION; CONTROLLED STUDY; DACTYLITIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; INFECTION; JOINT SWELLING; JOINT TENDERNESS; LATENT TUBERCULOSIS; LEUKOCYTE COUNT; LYMPHOMA; MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESITIS SCORE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; THROMBOCYTE COUNT; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS; WEIGHT CHANGE; WOUND INFECTION;

PSORIATIC ARTHRITIS; SPONDYLOARTHRITIS; TREATMENT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PSORIASIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84899981396     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205056     Document Type: Article

References (14)

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17. (Pubitemid 40288513)
2. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71: 319-26.
3. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71: 4-12.
4. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51: 1368-77.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61: 451-85.
6. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83: 1583-90.
7. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159: 842-55.
8. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54: 2665-73. (Pubitemid 44205029)
9. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: 727-35.
10. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebocontrolled study. Arthritis Rheum 2012;64: 3156-67.
11. Mease PJ. Measures of psoriatic arthritis: tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S64-85.
12. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382: 780-9.
13. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60: 976-86.
14. Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register-2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008;35: 668-73. (Pubitemid 351500064)